DK1406895T3 - Lactonformuleringer og fremgangsmåde til anvendelse deraf - Google Patents

Lactonformuleringer og fremgangsmåde til anvendelse deraf

Info

Publication number
DK1406895T3
DK1406895T3 DK02734779T DK02734779T DK1406895T3 DK 1406895 T3 DK1406895 T3 DK 1406895T3 DK 02734779 T DK02734779 T DK 02734779T DK 02734779 T DK02734779 T DK 02734779T DK 1406895 T3 DK1406895 T3 DK 1406895T3
Authority
DK
Denmark
Prior art keywords
methods
lactone
formulations
lactone formulations
Prior art date
Application number
DK02734779T
Other languages
English (en)
Inventor
David Terrero
Original Assignee
Magnachem Int Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnachem Int Lab Inc filed Critical Magnachem Int Lab Inc
Application granted granted Critical
Publication of DK1406895T3 publication Critical patent/DK1406895T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK02734779T 2001-06-13 2002-06-12 Lactonformuleringer og fremgangsmåde til anvendelse deraf DK1406895T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29787501P 2001-06-13 2001-06-13
PCT/US2002/018602 WO2002100854A1 (en) 2001-06-13 2002-06-12 Lactone formulations and method of use

Publications (1)

Publication Number Publication Date
DK1406895T3 true DK1406895T3 (da) 2008-12-01

Family

ID=23148076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02734779T DK1406895T3 (da) 2001-06-13 2002-06-12 Lactonformuleringer og fremgangsmåde til anvendelse deraf

Country Status (21)

Country Link
US (3) US6900242B2 (da)
EP (1) EP1406895B1 (da)
JP (1) JP2005500289A (da)
KR (1) KR20040030676A (da)
AR (1) AR036056A1 (da)
AT (1) ATE406367T1 (da)
AU (1) AU2002306150B2 (da)
BR (1) BR0210432A (da)
CA (1) CA2450660C (da)
CO (1) CO5550429A2 (da)
CY (1) CY1108590T1 (da)
DE (1) DE60228576D1 (da)
DK (1) DK1406895T3 (da)
ES (1) ES2315365T3 (da)
IL (3) IL159296A0 (da)
MX (1) MXPA03011554A (da)
PT (1) PT1406895E (da)
RS (1) RS52139B (da)
UY (1) UY27334A1 (da)
WO (1) WO2002100854A1 (da)
ZA (1) ZA200400208B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52139B (sr) 2001-06-13 2012-08-31 Magnachem International Laboratories Inc. Formulacije laktona i postupak za njihovo korišćenje
WO2004041217A2 (en) * 2002-11-05 2004-05-21 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
WO2005102315A1 (en) * 2004-04-23 2005-11-03 Magnachem International Laboratories, Inc. Synthetic lactone formulations for pain control
CN102265154A (zh) * 2008-10-24 2011-11-30 马格纳化学国际实验室公司 用于筛选与rad9选择性相互作用的化合物的方法
CN103099901B (zh) * 2013-01-26 2014-07-30 张红 一种治疗子宫内膜移位症的中药灌肠剂
KR101988479B1 (ko) * 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624723A (en) * 1947-03-03 1953-01-06 Allied Chem & Dye Corp Lactone derivatives and method of making
US2624732A (en) * 1950-05-10 1953-01-06 Burroughs Wellcome Co Preparation of 5-benzyl-2,4-diaminopyrimidines
US3203953A (en) * 1963-01-18 1965-08-31 Ciba Geigy Corp Lactone obtained from helenium sp. and derivatives thereof
US3210377A (en) * 1963-06-05 1965-10-05 Olin Mathieson Gamma lactones
US4001425A (en) * 1974-04-17 1977-01-04 E. I. Du Pont De Nemours And Company Methods of treating hypertension and pharmaceutical compositions comprising 1-tertiary-alkyl-3-(substituted furyl)ureas as antihypertensive agents
JPS5111173B2 (da) * 1974-04-25 1976-04-09
JPS51125722A (en) 1975-01-13 1976-11-02 Sumitomo Chem Co Ltd Germicides for industry and their preparation
JPS597713B2 (ja) 1977-12-19 1984-02-20 三井東圧化学株式会社 新規γ↓−ブチロラクトン誘導体とその製造法
JPS56128776A (en) 1980-03-14 1981-10-08 Otsuka Pharmaceut Factory Inc Alpha-methylene gamma-butyrolactone derivative
JPS58199413A (ja) 1982-05-13 1983-11-19 Pioneer Electronic Corp デイジタル変調信号の読取装置
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
JPS6226221A (ja) 1985-07-29 1987-02-04 Japan Tobacco Inc 抗変異原性剤
JP2524760B2 (ja) 1987-07-10 1996-08-14 テイカ株式会社 新規抗生物質
JPH01163175A (ja) 1987-12-21 1989-06-27 Ss Pharmaceut Co Ltd フラン−２−オン誘導体
US5242945A (en) * 1991-04-12 1993-09-07 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase a2 inhibitors
US5250735A (en) * 1992-04-03 1993-10-05 University Of Pittsburgh 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof
AU7636894A (en) * 1993-09-17 1995-04-03 Upjohn Company, The Substituted tetronic acids useful for treating hiv and other retroviruses
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0712843B1 (en) 1994-06-07 1999-11-17 Teijin Limited Vitamin d3 derivative and process for producing the same
AUPN191295A0 (en) 1995-03-23 1995-04-27 Unisearch Limited Microbiocide or microbial regulator
US5962460A (en) * 1995-06-27 1999-10-05 National Science Council (Taiwan) Antineoplastic α-methylene-γ-butyrolactones
US5646164A (en) * 1995-11-14 1997-07-08 National Science Council α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation
DE69635130T2 (de) 1995-11-17 2006-06-14 Univ Johns Hopkins Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
WO1998043966A1 (en) 1997-04-02 1998-10-08 Merck Frosst Canada & Co. Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
AUPP303498A0 (en) 1998-04-17 1998-05-14 Unisearch Limited Inhibition of gram positive bacteria
JP2002517423A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド シクロオキシゲナーゼ−２の多結合インヒビター
WO2000058297A2 (en) * 1999-03-30 2000-10-05 E.I. Du Pont De Nemours And Company PROCESS FOR THE PREPARATION OF α-METHYLENE LACTONES
FR2801792B1 (fr) 1999-12-01 2003-04-18 Sod Conseils Rech Applic Un nouveau medicament, le dihydromikanolide, son obtention par extraction de la plante mikania micrantha et son utilisation comme agent anti-proliferatif
US6660511B1 (en) 2000-03-03 2003-12-09 Rigel Pharmaceuticals, Inc. Methods of screening for modulation of cell cycle
CA2412651A1 (en) * 2000-05-22 2001-11-29 Dr. Reddy's Laboratories Limited Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
JP2002037797A (ja) * 2000-07-25 2002-02-06 Kanegafuchi Chem Ind Co Ltd マクロファージ選択的細胞死誘導物質
AU2002243552C1 (en) 2001-01-12 2006-08-31 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
RS52139B (sr) 2001-06-13 2012-08-31 Magnachem International Laboratories Inc. Formulacije laktona i postupak za njihovo korišćenje
US6686724B2 (en) * 2002-05-21 2004-02-03 Ford Motor Company Method of and apparatus for controlling charging and/or discharging of a battery for a hybrid electric vehicle
WO2004041217A2 (en) * 2002-11-05 2004-05-21 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
WO2005102315A1 (en) * 2004-04-23 2005-11-03 Magnachem International Laboratories, Inc. Synthetic lactone formulations for pain control

Also Published As

Publication number Publication date
RS52139B (sr) 2012-08-31
BR0210432A (pt) 2004-08-03
CO5550429A2 (es) 2005-08-31
PT1406895E (pt) 2008-11-04
CY1108590T1 (el) 2014-04-09
RS98603A (sr) 2006-12-15
US6900242B2 (en) 2005-05-31
DE60228576D1 (de) 2008-10-09
UY27334A1 (es) 2003-02-28
ATE406367T1 (de) 2008-09-15
US8536348B2 (en) 2013-09-17
EP1406895B1 (en) 2008-08-27
IL211958A0 (en) 2011-06-30
CA2450660A1 (en) 2002-12-19
AU2002306150B2 (en) 2008-02-14
ZA200400208B (en) 2005-06-29
EP1406895A1 (en) 2004-04-14
JP2005500289A (ja) 2005-01-06
IL159296A (en) 2011-06-30
EP1406895A4 (en) 2004-11-17
CA2450660C (en) 2011-08-16
AR036056A1 (es) 2004-08-04
US20050209316A1 (en) 2005-09-22
MXPA03011554A (es) 2004-10-28
WO2002100854A1 (en) 2002-12-19
US20030069393A1 (en) 2003-04-10
US20110092588A1 (en) 2011-04-21
KR20040030676A (ko) 2004-04-09
ES2315365T3 (es) 2009-04-01
IL159296A0 (en) 2004-06-01

Similar Documents

Publication Publication Date Title
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DK1242095T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
NO20041975L (no) Bicyklisk oksopyridin og oksopyrimidinderivater
DK1370128T3 (da) Kombineret ballepresse og ballevikler
DK1339292T3 (da) Sammensætning og fremgangsmåde
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20033556L (no) Farmasöytiske formuleringer
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
DK1429769T3 (da) Nye formuleringer og anvendelse deraf
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
ATE502118T1 (de) Amplifizierungsverfahren
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20043333L (no) Farmasoytiske parvastatinformuleringer og fremgangsmater for anvendelse av dem
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
DE60201856D1 (de) Klasse-D Verstärker
NO20030843L (no) Anordning og fremgangsmåte for kultivering
NO20030156D0 (no) Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
DK1406895T3 (da) Lactonformuleringer og fremgangsmåde til anvendelse deraf